Why aTyr Pharma, Inc.’s (ATYR) Stock Is Down 5.38%
As of Monday, July 13, aTyr Pharma, Inc.’s ATYR share price has dipped by 5.38%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Commentary & Analysis
Why aTyr Pharma, Inc.’s (ATYR) Stock Is Down 6.45%
As of Friday, July 10, aTyr Pharma, Inc.’s ATYR share price has dipped by 6.45%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why aTyr Pharma, Inc.’s (ATYR) Stock Is Down 5.40%
As of Thursday, July 09, aTyr Pharma, Inc.’s ATYR share price has dipped by 5.40%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why aTyr Pharma, Inc.’s (ATYR) Stock Is Up 10.53%
As of Wednesday, July 08, aTyr Pharma, Inc.’s ATYR share price has surged by 10.53%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why aTyr Pharma, Inc.’s (ATYR) Stock Is Up 6.21%
As of Monday, July 06, aTyr Pharma, Inc.’s ATYR share price has surged by 6.21%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | ATYR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $47.6 | $252.6 | 16% |
|
| Shares Out (Mil) | 98.0 | 52.3 | 62% |
|
| Institutional Ownership | 94.1% | 92.1% | 64% |
|
| Float (Mil) | 95.5 | 40.2 | 60% |
|
| Beta | 0.66 | 0.95 | 38% |
|
| Avg Daily Volume (000s) | 801 | 455 | 67% |
|
| Price Change (52-week) |
(90.2%) | 52.9% | 4% |
|
| Growth | ATYR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (54.7%) | 13.6% | 0% |
|
| Net Income (5yr) | (35.5%) | (9.9%) | 11% |
|
| EPS (5yr) | 14.8% | 16.0% | 55 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.0%) | (15.6%) | 52% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 8 | |
| Current EPS | ($0.129) | ($0.583) | ($0.628) | |
| Month Ago EPS | ($0.122) | ($0.542) | ($0.638) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.152) | ($0.609) | ($0.401) | |
| Year/Year Chg | 17.3% | (26.9%) | (30.7%) | |
| Financials | ATYR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $0 | $38 | 0% |
|
| Net Income (TTM) (Mil) | ($70) | ($43) | 13% |
|
| EPS (TTM) | ($0.730) | ($1.600) | 24% |
|
| Operating Cash Flow (TTM) (Mil) | ($59) | ($31) | 8% |
|
| Net Cash Flow (TTM) (Mil) | ($1) | $5 | 40% |
|
| Long-Term Debt (Q1) (Mil) | $10 | $5 | 28% |
|
| Enterprise Value (Q1) (Mil) | ($6) | $180 | 2% |
|
| Valuation | ATYR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.82 | 2.56 | 17% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | ATYR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (79.2%) | (49.8%) | 7% |
|
| ROE | (105.3%) | (55.5%) | 9% |
|
| Liabilities to Assets | 27.5% | 30.3% | 19% |
|
| F-Score | 1 | 3 | 1% |
|
Passing Stock Screens
As of 7/31/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Est Rev: Down 5% Screen
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 2.4% |
| +/- S&P 500: | -5.1 |
